What Clinicians Want to Know: Addressing Community Oncologists’ Questions About the Care of Patients with Prostate Cancer

Faculty

Faculty

Wassim Abida

MD, PhD

Memorial Sloan Kettering Cancer Center, New York, New York

Director of Translational Research in Prostate Cancer, Associate Member, Genitourinary Oncology Service

Weill Cornell Medical College, New York, New York

Associate Professor of Medicine

Faculty

Rahul Aggarwal

MD

Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco

Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research, Director, Genitourinary Medical Oncology

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Associate Director for Clinical Research

Faculty

Emmanuel S Antonarakis

MD

University of Minnesota Minneapolis, Minnesota

Clark Endowed Professor of Medicine Division of Hematology Oncology and Transplantation

Faculty

Professor Karim Fizazi

MD, PhD

University of Paris Saclay Centre Oscar Lambret Lille, France

GETUG President

Moderator

Rana R McKay

MD

Moores Cancer Center, University of California San Diego, San Diego, California

Professor of Medicine and Urology, Associate Director, Clinical Research, Co-Lead, Genitourinary Program

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (nmHSPC)

• Rationale for the evaluation of treatment intensification with androgen receptor (AR) pathway inhibitors for patients with nmHSPC
• Major efficacy and safety data, including overall survival outcomes, from the Phase III EMBARK trial evaluating enzalutamide and leuprolide versus enzalutamide or leuprolide alone for patients with nmHSPC and high-risk biochemical recurrence after definitive therapy
• FDA approval and optimal application of enzalutamide with and without androgen deprivation therapy (ADT) in clinical practice
• Published data with ADT intensification with apalutamide with or without abiraterone for patients with high-risk biochemically recurrent nmHSPC

MODULE 2: Current Hormonal Treatment for Metastatic HSPC (mHSPC)

• Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with mHSPC
• Published data from the Phase III ARANOTE study supporting the recent FDA approval of darolutamide/ADT for mHSPC
• Clinical factors guiding the selection of a specific AR pathway inhibitor for patients with mHSPC; available datasets exploring the relative benefits of various approved agents
• Published efficacy and safety data from the Phase III ARASENS trial evaluating darolutamide in combination with docetaxel and ADT for mHSPC
• Optimal selection of candidates with mHSPC for triplet therapy with darolutamide/docetaxel/ADT

MODULE 3: Current and Future Role of Regimens Combining PARP Inhibitors and AR Pathway Inhibitors in Treatment for Metastatic Prostate Cancer

• Incidence and clinical implications of BRCA1/2 and other homologous recombination repair (HRR) abnormalities in patients with metastatic prostate cancer; recommended timing and optimal method for genetic testing
• Biological rationale for combining PARP inhibitors with secondary hormonal agents in the treatment of metastatic prostate cancer
• Long-term efficacy and safety findings from the Phase III PROpel, MAGNITUDE and TALAPRO-2 trials combining olaparib and abiraterone, niraparib and abiraterone and talazoparib and enzalutamide, respectively, in the first-line setting for patients with metastatic castration-resistant prostate cancer (mCRPC)
• FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide for mCRPC; appropriate selection of a PARP inhibitor/secondary hormonal therapy combination for individual patients
• Presented data from the Phase III AMPLITUDE trial evaluating the addition of niraparib to abiraterone/prednisone for patients with mHSPC harboring alterations in HRR genes; clinical implications
• Ongoing Phase III TALAPRO-3 and EvoPAR-Prostate01 trials evaluating talazoparib and saruparib, respectively, in combination with secondary hormonal therapy for patients with mHSPC; anticipated completion dates

MODULE 4: Emerging Role of AKT Inhibition in Therapy for Patients with mHSPC

• Biological justification for targeting the PI3K/AKT/mTOR pathway with capivasertib in prostate cancer; rationale for benefit for patients with PTEN-deficient disease
• Frequency of PTEN deficiency in prostate cancer; indications for and optimal timing of and approach to PTEN assessment
• Design, eligibility criteria and primary and secondary endpoints of the Phase III CAPItello-281 trial assessing capivasertib with abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
• Recently presented positive results from the CAPItello-281 trial with the addition of capivasertib to abiraterone/ADT for PTEN-deficient mHSPC
• Spectrum of toxicities associated with capivasertib; recommended monitoring and management strategies
• Potential integration of capivasertib/abiraterone/ADT into mHSPC treatment algorithms; optimal use with regard to other currently available regimens

MODULE 5: Current and Future Use of Radiopharmaceuticals for Metastatic Prostate Cancer

• Long-term data with and current role of radium-223 monotherapy in mCRPC treatment algorithms
• Key efficacy and safety findings from the Phase III PEACE III trial of radium-223 and enzalutamide versus enzalutamide alone as first-line therapy for mCRPC with bone metastases; implications for clinical management
• Published Phase III datasets with lutetium Lu 177 vipivotide tetraxetan for patients with taxane-naïve and taxane-pretreated, PSMA-positive mCRPC; appropriate sequencing with regard to other available therapies
• Recently presented results from the Phase III PSMAddition study evaluating the addition of lutetium Lu 177 vipivotide tetraxetan to hormonal therapy for patients with PSMA-positive mHSPC; implications for clinical practice
• Early findings with and ongoing evaluation of other PSMA-targeted radiopharmaceuticals for metastatic prostate cancer

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to 

• Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for patients with consideration of the risks and potential benefits of new and established forms of hormonal therapy.
• Appraise published research findings on optimal therapeutic approaches for patients with biochemical recurrence after local therapy for prostate cancer, and counsel appropriate candidates regarding the potential benefits of FDA-approved systemic treatment options.
• Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options for patients.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and effectively integrate these strategies into clinical management algorithms.
• Assess the available research database supporting the use of PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
• Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway in prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
• Review available Phase III data documenting the efficacy of various forms of radioligand therapy for patients with metastatic prostate cancer, and consider the current and future clinical role of these strategies.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Abida — Advisory Committees: AstraZeneca Pharmaceuticals LP, K36 Therapeutics, Nuvation Bio Inc, ORIC Pharmaceuticals; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boundless Bio, Duality Biologics, Endeavor BioMedicines, Tolmar; Contracted Research: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, K36 Therapeutics, Merus, MOMA Therapeutics, Nuvation Bio Inc, ORIC Pharmaceuticals, TransThera. Dr Antonarakis — Advisory Committees: Bayer HealthCare Pharmaceuticals, DAVA Oncology, EcoR1 Capital LLC, Janssen Biotech Inc, Johnson & Johnson, Lilly, Merck, Pfizer Inc, Tango Therapeutics, Tempus, Z-Alpha; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, MacroGenics Inc, Merck, Novartis, Orion Corporation, pharmaand GmbH, Seagen Inc; Honoraria: ClearView Healthcare Partners, Curium, Lilly, Merck; Nonrelevant Financial Relationships: Fred Hutch Cancer Center, The Medical Educator Consortium. Additional faculty to be announced.

MODERATOR
Dr McKay — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Astellas and Pfizer Inc, Merck, and Novartis.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.